Бромкамфора (Bromocamphor) is categorized within the therapeutic group of other hypnotics and sedatives, and is commonly used for managing nervous system distress.

This medication is applied across domains where additional symptomatic support is needed, and is used in situations involving certain distressing symptoms related to functional nervous instability. It is commonly used to help with emotional excitation, restlessness, and chronic irritability frequently observed in conditions like neurasthenia and other mild, functional neurotic states.

“The calming effect supports patients during episodes of heightened discomfort and assists with maintaining functional stability.”

The supportive benefit generally contributes to easing the overall symptom burden when nervous tension is pronounced or interferes with daily functioning. In clinical contexts, it is considered relevant for long-term functional complaints characterized by persistent nervous weariness, as well as for managing sleeplessness and functional somatic stress manifestations (such as mild tremors or palpitations) which are symptoms of increased neurological activity. The supportive relief offered may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Nervous Tension This medication is generally applied in situations where symptoms are driven by functional nervous instability, rather than acute organic disease, and is relevant when supportive symptom management is appropriate.

Regulatory References

1. WHO Anatomical Therapeutic Chemical (ATC) Classification

The eligibility profile for Бромкамфора (Bromocamphor) is strictly defined by regulatory authorities based on patient status, organ function, and age. Use of the medicine is definitively contraindicated in several specific patient groups as stated in the official labeling.

Absolute Contraindications

Absolute prohibition applies to individuals with severe impairment of vital organs, including severe hepatic insufficiency (liver failure) and severe renal insufficiency (kidney failure). The medicine is also strictly contraindicated for women who are pregnant or actively breastfeeding (lactating). Any known hypersensitivity to Bromocamphor, bromides, or related camphor derivatives constitutes an absolute bar to use. Additionally, patients with certain digestive disorders, such as lactose intolerance, are excluded due to tablet excipients.

Age and Conditional Use

The medicine is contraindicated for the pediatric population under 7 years of age; use is only established for children aged 7 years and above, and for adults. Furthermore, use requires explicit caution in geriatric patients (older adults) and in individuals with a history of epilepsy or tendencies toward convulsive reactions.

Interactions with other medicines and products

The official interaction profile for Бромкамфора (Bromocamphor) is primarily defined by its regulatory classification as a sedative and Central Nervous System (CNS) depressant. This classification mandates the documentation of pharmacodynamic interactions that result in an additive effect when co-administered with other substances that also depress the CNS.

---

Pharmacodynamic and Substance Interactions

The most clinically relevant interaction involves the reinforcement of CNS depressant effects. Regulatory documents state that co-administration with other psycholeptics, anxiolytics, sedatives, or hypnotics may potentiate the central sedative action of Bromocamphor, increasing the risk of drowsiness. A specific and mandatory restriction documented in prescribing information concerns the co-administration of alcohol (ethanol). Consumption of alcohol enhances the CNS depressant effect, leading to an increased severity of sedation and potential impairment of coordination; therefore, co-use is strictly restricted.

---

Pharmacokinetic and Timing Constraints

The official regulatory profile does not document specific interactions involving the alteration of drug levels (pharmacokinetics). No interactions mediated by cytochrome P450 (CYP) enzymes or major drug transporters (such as P-glycoprotein) are listed in official government prescribing information. Similarly, the drug’s labeling does not include specific timing-based interaction rules that require the separation of Bromocamphor doses from other co-administered medicinal products. No population-specific interaction cautions (e.g., heightened risk in hepatic impairment) are explicitly documented beyond general warnings.

Functional Depression of Central Neuronal Excitability

This compound functions as a non-specific functional inhibitor within the central nervous system ( CNS) by influencing neuronal excitability and membrane function. Due to its lipophilic nature, the molecule rapidly crosses the blood-brain barrier ( BBB) and increases the electrical threshold required for central nerve cells to fire, extbfreducing the rate of spontaneous neural firing. This molecular action modifies early steps in the signaling cascade, leading to a generalized reduction in CNS activity.

---

Modulation of Arousal and Affective Networks

The inhibitory effect is functionally concentrated in extbfsubcortical arousal centers, including components of the Reticular Activating System ( RAS) and the limbic system, which function in maintaining cortical arousal and processing affective signals. By extbfslowing the rate of signal flow through these key regulatory networks, the mechanism produces a systemic decrease in central nervous system excitability. The resulting functional depression in arousal centers constitutes the drug's core action profile.

---

Limitations of Non-Specific Action

The mechanism of Bromocamphor is defined by this broad inhibitory influence rather than high-affinity, specific receptor modulation. This extbfnon-selective action means the resulting CNS depression is broadly distributed across CNS functional areas. This functional non-specificity determines the scope and character of the inhibitory physiological consequence.

Official Administration Protocol

Administration of Bromocamphor is based on established prescribing parameters which detail the precise route, dosing, frequency, and duration of use. The medication is formulated as a 250 mg tablet for oral administration.

Dosing and Frequency

For adults (age 14 and older), the standard administration involves a dosage range of 250 mg to 500 mg per dose. This is typically taken two to three times per day, and the maximum total daily intake is limited to 1500 mg (1.5 g).

Pediatric administration follows a lower, age-specific protocol. Children aged 7 to 10 years are prescribed 250 mg twice daily, with a daily maximum of 500 mg. Adolescents aged 10 to 14 years may take 250 mg two to three times daily, not to exceed 750 mg in a 24-hour period.

Procedural Constraints

A key procedural constraint in the protocol is the timing of administration: the tablet is taken after meals. The solid form is intended to be swallowed whole. Usage is not indefinite; the entire course of administration is constrained to a duration of 10 to 15 days, which defines the short-term use pattern of the medicine. The administration protocol is based on a fixed, divided daily schedule, ensuring adherence to the maximum daily limits.

Research evidence / Overview of studies

---

Overview of Clinical Research

Studies have investigated whether Bromcamphor is associated with changes in certain biological markers. Research has explored the drug’s potential effect on cognitive function. Findings have ranged from measurable differences in certain tests to no significant change, with evidence remaining limited in scope across various patient populations.

Research has examined outcomes related to pain reduction and the onset of relief in participants. Various trials examined specific administration protocols in study participants and reported on the corresponding changes in pain scores over specific periods. Research reports on specific patient populations and conditions that were excluded from the studies.

---

Research on Combined Regimens

A number of studies have focused on the use of the drug alongside established regimens. Research has explored whether the combination has an association with overall quality of life, using standardized participant questionnaires. Research has examined this approach through open-label and controlled trial designs.

Studies have investigated the duration of changes in symptom levels across several small-scale trials. The research focused on outcomes measured after the cessation of the study treatment. The research did not investigate the sequence of administration across different regimens.

---

Comparison to Control Groups

Research has explored whether study participants showed differences in outcomes when compared to placebo. Reported metrics included changes in disease activity scores and participant-reported measures of wellness. Research documented the frequency of reported side effects and adverse events. The duration of observed differences was a primary focus for most of the included research.

Common questions about Бромкамфора (FAQ)

Q: Are there any known side effects like drowsiness or dizziness?

A: Official regulatory prescribing information for this finished drug product currently does not provide a categorized list detailing the frequency of specific side effects. However, the medicine is classified as a Central Nervous System (CNS) Depressant and Sedative-Anxiolytic Agent. Due to its known action profile, the medication is indicated to influence neural activity, and like other CNS depressants, there may be an association with effects such as sedation.

Q: Are there any drug-drug interactions mediated by CYP enzymes?

A: According to the official product information, no specific drug-drug interactions involving Cytochrome P450 (CYP) enzymes are documented. These enzyme systems are part of the body's process for breaking down and clearing many medications, but the regulatory labeling does not include specific cautions regarding CYP-mediated effects.

Q: Does taking this drug affect my quality of life?

A: Official documentation mentions that research has been conducted to explore the association between the drug's use, particularly in combination with established regimens, and participant-reported quality of life measures. However, the specific conclusions or findings from these studies are not detailed within the regulatory summaries.

Q: Can this drug be used if a patient has a history of epilepsy?

A: Official prescribing information states that use of this medication requires explicit caution in individuals with a history of epilepsy or a tendency toward convulsive reactions. This caution is a key part of the eligibility profile for the medication.

How to Store and Dispose of Бромкамфора?

Regulatory documentation defines specific requirements for the storage and disposal of Bromocamphor (Бромкамфора) to ensure product stability and safety. These rules are non-advisory and reflect official label instructions.

Official Storage and Disposal Profile

Requirement Area	Mandatory Condition
Storage Environment	Store in a cool, dry place and protect from light due to its known chemical sensitivity. Avoid exposure to excessive heat.
Containment	Keep the product in its container, which must be tightly closed.
Child Safety	Mandatory instruction to keep the medication out of the reach of children.
Disposal Rule	Do not flush or dispose of the product in household trash, drains, or waterways.
Disposal Method	Dispose of unused or expired product at an approved waste facility, strictly following local and national regulations.